trending Market Intelligence /marketintelligence/en/news-insights/trending/GrOKFKtmNZ9RY17HXBLpZg2 content esgSubNav
In This List

Eli Lilly to collaborate with KeyBioscience for treating metabolic disorders

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Eli Lilly to collaborate with KeyBioscience for treating metabolic disorders

Eli Lilly & Co. entered an agreement with KeyBioscience AG to develop dual amylin calcitonin receptor agonists, or DACRAs — a potential new class of treatments for metabolic disorders such as type 2 diabetes.

The collaboration includes access to the DACRA platform with multiple molecules including KBP-042, KBP-089 and KBP-056.

KeyBioscience will receive $55 million in up-front payment as well as milestone-related payments and royalties on the future sales of successful candidates.

KeyBioscience has initiated phase 2 development with KBP-042. Other assets range from phase 1 to preclinical.

The transaction is subject to antitrust approval.